A Trial for New Treatment of Adult Participants With Irritable Bowel Syndrome

Summary

A study to evaluate the effectiveness of oral doses of Blautix in adult participants with irritable bowel syndrome (IBS).

Timeline

Start

2018-10-11

Primary completion

2020-05-13

Completion

2020-05-13

Outcome

Missed primary endpoint

registry Cohort C: Blautix vs Cohort C: Placebo; p = 0.152; Difference in Percentage 7.9 (95% CI -6.0 to 21.9) NCT03721107 ↗

registry Cohort D: Blautix vs Cohort D: Placebo; p = 0.216; Difference in Percentage 5.6 (95% CI -6.8 to 18.0) NCT03721107 ↗

Publications

• Quigley EMM, Markinson L, Stevenson A, Treasure FP, Lacy BE. Randomised clinical trial: efficacy and safety of the live biotherapeutic product MRx1234 in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2023 Jan;57(1):81-93. doi: 10.1111/apt.17310. Epub 2022 Nov 11.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Blautix	Unknown	—	—

Indications